Brian Fox

Brian Fox, PhD, currently serves as a Staff Scientist at Stealth NewCo since March 2024 and has been with Denali Therapeutics since 2016, holding various titles including Staff Scientist, Senior Director, and Director. Prior to Denali Therapeutics, Brian Fox worked at 3-V Biosciences as Associate Director of Chemistry and at Amgen as a Principal Scientist, where notable contributions included leading a medicinal chemistry team to develop the MDM2-p53 inhibitor AMG 232 and achieving in vivo proof of concept for an EP2 antagonist as a potential Alzheimer’s treatment. Earlier experience at Tularik involved significant contributions to the discovery of a DGAT1 inhibitor for metabolic disorders. Brian Fox obtained a PhD in Synthetic Medicinal Chemistry from Purdue University and a B.S. in Chemistry from Saint Louis University.